Van Bocxlaer, Katrien;
Gaukel, Eric;
Hauser, Deirdre;
Park, Seong Hee;
Schock, Sara;
Yardley, Vanessa;
Randolph, Ryan;
Plattner, Jacob J.;
Merchant, Tejal;
Croft, Simon L.;
Jacobs, Robert T.;
Wring, Stephen A.
Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles
Contributor:
Van Bocxlaer, Katrien;
Gaukel, Eric;
Hauser, Deirdre;
Park, Seong Hee;
Schock, Sara;
Yardley, Vanessa;
Randolph, Ryan;
Plattner, Jacob J.;
Merchant, Tejal;
Croft, Simon L.;
Jacobs, Robert T.;
Wring, Stephen A.
imprint:
American Society for Microbiology, 2018
Published in:Antimicrobial Agents and Chemotherapy
Description:
<jats:title>ABSTRACT</jats:title>
<jats:p>
Cutaneous leishmaniasis (CL) is caused by several species of the protozoan parasite
<jats:named-content content-type="genus-species">Leishmania</jats:named-content>
, affecting an estimated 10 million people worldwide. Previously reported strategies for the development of topical CL treatments have focused primarily on drug permeation and formulation optimization as the means to increase treatment efficacy. Our approach aims to identify compounds with antileishmanial activity and properties consistent with topical administration. Of the test compounds, five benzoxaboroles showed potent activity (50% effective concentration [EC
<jats:sub>50</jats:sub>
] < 5 μM) against intracellular amastigotes of at least one
<jats:named-content content-type="genus-species">Leishmania</jats:named-content>
species and acceptable activity (20 μM < EC
<jats:sub>50</jats:sub>
< 30 μM) against two more species. Benzoxaborole compounds were further prioritized on the basis of the
<jats:italic>in vitro</jats:italic>
evaluation of progression criteria related to skin permeation, such as the partition coefficient and solubility. An MDCKII-hMDR1 cell assay showed overall good permeability and no significant interaction with the P-glycoprotein transporter for all substrates except LSH002 and LSH031. The benzoxaboroles were degraded, to some extent, by skin enzymes but had stability superior to that of
<jats:italic>para</jats:italic>
-hydroxybenzoate compounds, which are known skin esterase substrates. Evaluation of permeation through reconstructed human epidermis showed LSH002 to be the most permeant, followed by LSH003 and LSH001. Skin disposition studies following finite drug formulation application to mouse skin demonstrated the highest permeation for LSH001, followed by LSH003 and LSH002, with a significantly larger amount of LSH001 than the other compounds being retained in skin. Finally, the efficacy of the leads (LSH001, LSH002, and LSH003) against
<jats:named-content content-type="genus-species">Leishmania major</jats:named-content>
was tested
<jats:italic>in vivo</jats:italic>
. LSH001 suppressed lesion growth upon topical application, and LSH003 reduced the lesion size following oral administration.
</jats:p>